NAS:GLMD (Israel) Also trade in: Germany

Galmed Pharmaceuticals Ltd

$ 6.88 -0.07 (-1.01%)
Volume: 23,484 Avg Vol (1m): 119,803
Market Cap $: 145.26 Mil Enterprise Value $: 58.70 Mil
P/E (TTM): 0.00 P/B: 1.73
Earnings Power Value 2.48
Net Current Asset Value 3.99
Tangible Book 4.03
Projected FCF -1.13
Median P/S Value 8.03
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
75.14% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
GLMD: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.39, Med: 10000, Max: 10000
Current: 10000
0.39
10000
Interest Coverage No Debt
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
GLMD: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 29.83
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 18.15%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -598.43
Operating Margin ranked lower than
76.26% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
GLMD: -598.43
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -3614.99, Med: -1139.54, Max: -525.76
Current: -598.43
-3614.99
-525.76
Net Margin % -531.99
Net Margin ranked lower than
77.27% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
GLMD: -531.99
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3630.19, Med: -1133.55, Max: -483.61
Current: -531.99
-3630.19
-483.61
ROE % -14.72
ROE ranked lower than
50.86% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
GLMD: -14.72
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -103.94, Med: -61.81, Max: -14.72
Current: -14.72
-103.94
-14.72
ROA % -14.17
ROA ranked lower than
53.32% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
GLMD: -14.17
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -3768.32, Med: -68.15, Max: -14.17
Current: -14.17
-3768.32
-14.17
ROC (Joel Greenblatt) % -4137.04
ROC (Joel Greenblatt) ranked lower than
70.17% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
GLMD: -4137.04
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -67730.23, Med: -2108.93, Max: -314.1
Current: -4137.04
-67730.23
-314.1
3-Year Total EBITDA Growth Rate 1.60
3-Year EBITDA Growth Rate ranked lower than
59.48% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
GLMD: 16.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.9, Med: -2.8, Max: 16.4
Current: 16.4
-31.9
16.4
3-Year EPS w/o NRI Growth Rate 17.50
3-Year EPS w/o NRI Growth Rate ranked lower than
60.42% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
GLMD: 17.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 6.9, Max: 24.4
Current: 17.5
0
24.4

» GLMD's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GLMD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:142760 ROCO:6575 NAS:VSTM NAS:MNLO XKRX:166480 NAS:OCUL TSE:4596 ROCO:6492 TSE:4564 TPE:1701 HKSE:01035 NAS:LQDA TPE:4142 OCSE:ORPHA XMAD:ORY ROCO:4167 NAS:TYME XSWX:NWRN NAS:EYPT XBRU:OXUR
Traded in other countries GPH.Germany
Address 16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Ratios

Current vs industry vs history
PB Ratio 1.73
PB Ratio ranked higher than
72.97% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
GLMD: 1.73
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.12, Med: 4.51, Max: 18.06
Current: 1.73
1.12
18.06
PS Ratio 77.30
PS Ratio ranked lower than
88.84% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
GLMD: 77.3
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 58.92, Med: 90.23, Max: 307.06
Current: 77.3
58.92
307.06
EV-to-EBIT -4.80
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
GLMD: -4.8
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -18.9, Med: -6.2, Max: -0.6
Current: -4.8
-18.9
-0.6
EV-to-EBITDA -4.95
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
GLMD: -4.95
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -19.5, Med: -6.3, Max: -0.6
Current: -4.95
-19.5
-0.6
EV-to-Revenue 28.78
EV-to-Revenue ranked lower than
84.31% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
GLMD: 28.78
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 6.4, Med: 70.8, Max: 206.7
Current: 28.78
6.4
206.7
Current Ratio 36.11
Current Ratio ranked higher than
93.67% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
GLMD: 36.11
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.09, Med: 9.2, Max: 53.98
Current: 36.11
0.09
53.98
Quick Ratio 36.11
Quick Ratio ranked higher than
93.67% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
GLMD: 36.11
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.09, Med: 9.2, Max: 53.98
Current: 36.11
0.09
53.98
Days Sales Outstanding 74.68
Days Sales Outstanding ranked lower than
83.23% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
GLMD: 74.68
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 9.13, Med: 18.5, Max: 74.68
Current: 74.68
9.13
74.68

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.80
3-Year Share Buyback Rate ranked higher than
69.08% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
GLMD: -17.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -17.8, Med: -11.7, Max: -4.4
Current: -17.8
-17.8
-4.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.71
Price-to-Tangible-Book ranked higher than
79.08% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
GLMD: 1.71
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.62, Med: 3.45, Max: 17.73
Current: 1.71
1.62
17.73
Price-to-Median-PS-Value 0.86
Price-to-Median-PS-Value ranked lower than
76.11% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
GLMD: 0.86
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.7, Med: 1.02, Max: 2.9
Current: 0.86
0.7
2.9
Earnings Yield (Joel Greenblatt) % -20.79
Earnings Yield (Greenblatt) ranked higher than
51.62% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
GLMD: -20.79
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -169.5, Med: -16, Max: -5.3
Current: -20.79
-169.5
-5.3

More Statistics

Revenue (TTM) (Mil) $ 2.04
EPS (TTM) $ -0.57
Beta 2.7
Volatility % 102.46
52-Week Range $ 5.58 - 27.06
Shares Outstanding (Mil) 21.11

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y